About 260 Mg-43.4 Ml Paclitaxel Injection IP
Introducing the redoubtable 260 Mg-43.4 Ml Paclitaxel Injection IP-your Last Chance to redeem an exclusive, world-class oncology solution widely recognized under virtuoso brand names like Taxol. Crafted to GMP standards and delivered in a USP type-1 glass vial with flip-off seal for assured sterility, this prescription-only, cytotoxic agent is indicated for breast, ovarian, non-small cell lung cancers, and AIDS-related Kaposi's sarcoma. Soluble in specialized carriers, compatible for precise dilution, and stable for up to 27 hours, it offers ready-to-use convenience for trained professionals. Handle with care. Distributor, exporter, supplier, trader-India.
Clinical Applications and Exclusive Features
260 Mg-43.4 Ml Paclitaxel Injection IP is used as a potent treatment for multiple malignancies, including ovarian, breast, and non-small cell lung cancers, as well as AIDS-related Kaposi's sarcoma. Its sterile, preservative-free single-dose vial ensures safe intravenous infusion via a robust USP type-1 glass container. The solution, clear and colorless to pale yellow, is uniquely prepared for optimal patient safety and compatibility with standard dilution fluids.
Sample Availability and Streamlined Packaging
Request a sample and experience the swift dispatching of Paclitaxel Injection IP. We ensure securely packaged goods in protective USP type-1 glass vials with rubber stoppers and flip-off seals. Shipped goods maintain their integrity throughout transit, while typical delivery time can be discussed based on your asking price and shipping preference. Commitment to pharmaceutical excellence guarantees readiness and prompt shipment to meet your requirements.
FAQ's of 260 Mg-43.4 Ml Paclitaxel Injection IP:
Q: How should Paclitaxel Injection IP be prepared and administered?
A: Paclitaxel Injection IP should be diluted with 0.9% sodium chloride or 5% dextrose solution and administered via intravenous infusion only. An in-line filter is recommended during infusion to ensure patient safety.
Q: What precautions are necessary before starting treatment with Paclitaxel Injection IP?
A: Patients should receive premedication with corticosteroids and antihistamines to reduce the risk of hypersensitivity reactions. Handling and administration should only be performed by trained professionals due to the cytotoxic nature of the drug.
Q: When is Paclitaxel Injection IP indicated for use?
A: This injection is indicated for the treatment of ovarian cancer, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi's sarcoma, as prescribed by a physician.
Q: How stable is Paclitaxel Injection IP after dilution?
A: Once diluted as per the recommended guidelines, Paclitaxel Injection IP remains stable for up to 27 hours at room temperature, provided it is protected from light and not frozen.
Q: What are the packaging and storage instructions for Paclitaxel Injection IP?
A: Each batch is packaged in a USP type-1 glass vial with rubber stopper and flip-off seal. The product should be stored below 25C, protected from light, and must not be frozen to ensure efficacy.
Q: What is the process to request a sample or inquire about delivery time?
A: Samples are available upon request. Once your order and asking price are confirmed, goods are dispatched and shipped promptly according to your specified delivery schedule and packaging requirements.